Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

OcuHist

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved January 1996

Specific Treatments:

itching and redness of the eye

General Information

OcuHist has been approved as an over-the-counter antihistamine eye drop. Akorn, previously marketed this formulation as the prescription drug AK-Con-A.

With its active antihistamine ingredient pheniramine maleate (0.3%), and decongestant ingredient naphazoline hydrochloride (0.025%), OcuHist temporarily relieves itching and redness of the eye due to pollen, ragweed, grass, animal hair, and dander.

Additional Information

An estimated 50 million Americans are afflicted by pollen, ragweed, and other irritants.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation